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Provider-initiated partner notification for HIV effectively identifies new cases of
HIV in sub-Saharan Africa, but is not widely implemented. Our objective was to
determine whether provider-based HIV partner notification strategies are
cost-effective for preventing HIV transmission compared with passive referral.
We conducted a cost-effectiveness analysis using a decision-analytic model from
the health system perspective during a 1-year period. Costs and outcomes of
all strategies were estimated with a decision-tree model. The study setting was
an urban sexually transmitted infection clinic in Lilongwe, Malawi, using a
hypothetical cohort of 5000 sex partners of 3500 HIV-positive index cases. We
evaluated three partner notification strategies: provider notification (provider
attempts to notify indexes’ locatable partners), contract notification (index given
1 week to notify partners then provider attempts notification) and passive
referral (index is encouraged to notify partners, standard of care). Our main
outcomes included cost (US dollars) per transmission averted, cost per new case
identified and cost per partner tested. Based on estimated transmissions in
a 5000-person cohort, provider and contract notification averted 27.9 and 27.5
new infections, respectively, compared with passive referral. The incremental
cost-effectiveness ratio (ICER) was $3560 per HIV transmission averted for
contract notification compared with passive referral. Provider notification was
more expensive and slightly more effective than contract notification, yielding
an ICER of $51 421 per transmission averted. ICERs were sensitive to the
proportion of partners not contacted, but likely HIV positive and the probabil-
ity of transmission if not on antiretroviral therapy. The costs per new
case identified were $36 (provider), $18 (contract) and $8 (passive). The costs
per partner tested were $19 (provider), $9 (contract) and $4 (passive).
We conclude that, in this population, provider-based notification strategies
are potentially cost-effective for identifying new cases of HIV. These strategies
offer a simple, effective and easily implementable opportunity to control HIV
transmission.
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 Partner notification for HIV is a simple, effective and easily implementable strategy in sub-Saharan African settings.
 Provider-initiated partner notification for HIV is reasonably cost-effective in the Malawian setting in terms of dollars
per transmission averted.
 Provider-initiated partner notification for HIV is an inexpensive opportunity to identify new cases of HIV and link
patients to care earlier.
Introduction
A substantial portion of HIV transmission is attributable to
persons unaware of their HIV-positive status (Marks et al. 2006;
CDC 2008). This transmission pattern is also expected in
more resource-limited settings. Interventions targeting these
individuals are critical for HIV prevention. One important and
accessible group of persons unaware of their status is sexual
partners of persons with newly diagnosed HIV infection. These
partners, if not already infected, are at high risk of acquiring
infection due to their ongoing exposure to the virus. Identifying
and testing sexual partners of persons recently diagnosed with
HIV may be an important component of expanded prevention
and treatment services.
Partner notification effectively identifies new cases of HIV
infection in high-income countries (Landis et al. 1992; Mathews
et al. 2002; Brewer 2005; Hogben et al. 2007; Golden et al. 2009;
Marcus et al. 2009). In partner notification, sexual partners of a
newly diagnosed person with HIV (index) are notified of their
potential exposure and encouraged to seek testing. Partner
notification strategies include ‘provider notification’, where a
medical provider notifies the exposed partner(s); ‘contract
notification’, where the index patient attempts to notify
partner(s) within 1–2 weeks, after which the provider completes
the notification process and ‘passive referral’, where the index
patient notifies partner(s) without any direct provider contact.
Provider and contract notifications for syphilis and HIV infec-
tion have been mainstays of public health control efforts in
high-income countries (European Partner Notification Study
2001; CDC 2003). Provider-based notification strategies increase
the rate of partner testing (Mathews et al. 2002) and, although
costs vary across sites (Shrestha et al. 2009), are believed to
be cost-effective for preventing future cases of HIV infection
in high-income countries (Rahman et al. 1998; Varghese et al.
1999).
Despite its success in high-income countries, provider-based
partner notification has not been widely adopted in sub-
Saharan Africa. However, in Malawi and Cameroon, provider
and contract notification appear to be feasible and effective in
identifying previously unknown infected persons and linking
these persons to care (Muffih et al. 2009; Brown et al. 2011).
In Malawi, rates of partner return were twice as high with
provider-based notification, compared with passive referral in a
randomized trial (Brown et al. 2011). Among partners who
presented for testing, 64% tested HIV positive; of partners
testing positive, most (81%) were new diagnoses. Many (28%)
were eligible for antiretroviral therapy (ART) based on Malawi’s
national guidelines of CD4 250 cells/mm3. The programme
was well accepted among sexually transmitted infection (STI)
patients, with only 11% of eligible index cases refusing
participation.
In this study, we evaluated the cost-effectiveness of partner
notification strategies to identify sexual partners of HIV-
infected index patients at STI clinics in Lilongwe, Malawi.
We estimated the costs associated with tracing and testing
locatable partners. We modelled transmission rates and
behavioural modifications after testing to evaluate cost per
partner tested, cost per new case identified and cost-effective-
ness of HIV transmissions averted by each notification strategy.
We compared our estimates of cost-effectiveness to those of
widely accepted transmission prevention interventions, such as
HIV testing and counselling (HTC) and nevirapine to prevent
mother-to-child transmission (Sweat et al. 2004; Menzies et al.
2009; Orlando et al. 2010). To our knowledge, this study is the
first cost-effectiveness analysis of partner notification in the
sub-Saharan African context.
Methods
We developed a decision-tree model (Figure 1), constructed
using ExcelTM 2010 (Microsoft Corp, Redmond, WA, USA), to
simulate costs, outcomes and incremental cost-effectiveness
ratios (ICERs) of implementing partner notification for HIV in
STI clinics in Lilongwe, Malawi. We used a health system
perspective, incorporating system-level costs incurred by tra-
cing, testing and treating eligible partners. Indirect patient costs
(i.e. travel time, lost wages, etc.) were not considered. Costs
and outcomes were evaluated during 1 year of programme
operation.
We used the trial of partner notification in an STI clinic
in Lilongwe as the primary basis for the model (Table 1)
(Brown et al. 2011). We obtained other parameter estimates
from relevant studies conducted in Malawi or elsewhere in
sub-Saharan Africa. The principal outcome was the number and
cost per secondary infection avoided as a result of integrating
partner notification in this setting. Additional outcomes
included the cost per new case identified and cost per partner
tested.
Transmissions and infections averted
We built a partner-centric model following a hypothetical
cohort of 5000 men and women aged 15–49 years who are
partners of indexes at an STI clinic. Index cases on average
report 1.4 locatable partners (Brown et al. 2011). Therefore, the
5000 partner hypothetical cohort corresponds to 3500 index
cases. In this cohort, locatable partners of the index case
received provider notification, contract notification or passive
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referral. Locatable partners are partners that the index reports
having had sexual contact with within the past 3 months and
for whom the index has either a phone number or address.
Success of the programme was modelled based on varying
partner return rates (Brown et al. 2011, Antelman et al. 1999,
Kilewo et al. 1999, and Temmerman et al. 1995). Transmission
events can be from the index to a negative partner or from a
positive partner to a person other than the index.
The stage of infection at diagnosis [acute, chronic or treatment
eligible (i.e. CD4 250 cells/mm3)] predicts likelihood of HIV
transmission (Leynaert et al. 1998; Wawer et al. 2005; Girardi et al.
2007; Hollingsworth et al. 2008). We used estimates that reflect
the distribution of disease stage at diagnosis as observed at a
Lilongwe STI clinic, excluding acute infection in that it is not
screened for in the setting of interest. Twenty-eight per cent of
partners (range 0.224–0.336) were eligible for ART at baseline
(CD4 250 cells/mm3) (Powers et al. 2007; Brown et al. 2011).
Transmission probabilities were based on observed transmissions
among serodiscordant couples in Uganda and are independent of
coital frequency, representing probability of transmission during
12 months (Hollingsworth et al. 2008). We assumed that all
partners who are tested and eligible for treatment according to
Malawian guidelines will begin ART immediately, with retention
in care across 1 year at 70% (Rosen and Fox 2011). The reduced
Figure 1 Decision tree modelling three strategies for partner notification. Partners of index patients may be notified of their exposure to HIV by
provider notification, contract notification or passive referral. Partners who return to the clinic and agree to HIV testing may test positive or negative,
and those partners who test positive may be in the chronic phase of infection and not treatment eligible, or may be eligible for treatment (CD4
250 cells/mm3). Persons who test and are HIV negative may change their sexual risk behaviours, affecting their risk of acquisition in their
serodiscordant partnership with the index partner. Transmission probabilities from positive partners account for the variability of infectivity at
different stages of infection, as well as reduced infectiousness for those who are eligible and retained on ART. Transmission also accounts for
the probability of HIV-infected partners in the cohort having sexual partnerships with HIV-negative persons outside of the index partnership.
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Table 1 Model input parameters
Parameter Base case (range) References
Probability of partner return and testing
Return (PN) 0.51 (0.4–0.73) Brown et al. (2011)
Return—traced (CN) 0.18 (0.144–0.216) Brown et al. (2011) and Muffih et al. (2009)
Return—not traced (CN) 0.33 (0.264–0.396) Brown et al. (2011)
Return (PR) 0.24 (0.14–0.34) Brown et al. (2011), Antelman et al. (1999), Kilewo et al (1999)
and Temmerman et al (1995)
Test (PN) 0.95 (0.8–1.0) Brown et al. (2011) and Muffih et al. (2009)
Test (CN) among traced partners 0.97 (0.8–1.0) Brown et al. (2011) and Muffih et al. (2009)
Test (CN) among not traced partners 1.0 (0.8–1.0) Brown et al. (2011)
Test (PR) 1.0 (0.8–1.0) Brown et al. (2011)
HIV prevalence and disease stage among partners (%)
Antibody positive (PN, CN and PR) 0.64 (0.51–0.77) Brown et al. (2011), Muffih et al. (2009) and Temmerman et al (1995)
Antibody positive, no return (PN, CN and PR) 0.64 (0.34–0.94) Assumed
End-stage if antibody positive 0.28 (0.224–0.336) Brown et al. (2011)
New diagnosis if antibody positive 0.81 (0.648–0.972) Brown et al. (2011)
Acute if antibody negative 0.0325 (0.02–0.045) Brown et al. (2011), Powers et al. (2007) Pilcher et al. 2004
and Pilcher et al (2007)
Behaviour change and transmission probabilities
Behaviour change if negative 0.35 (0.2–0.5) Allen et al. (1992, 2003), Baeten et al. (2012), Celum et al. (2010),
Voluntary HIV-1 Counseling and Testing Efficacy
Study Group (2000), Cohen et al. (2011), Denison et al. (2008),
Hughes et al. (2012), Kennedy et al. (2010) and
Rosenberg et al. (2012)
Transmission if behaviour change 0 Assumed
Partnership probabilities
Index patient is sole partner 0.7 (0.5–0.82) Brown et al. (2011) and Allen et al. (2003)
Outside partner is HIV positive 0.141 (0.069–0.214) UNAIDS (2009) and WHO (2008)
Probability of transmission (no behaviour change)
Acute 0.1975 (0.105–0.2875) Hollingsworth et al. (2008)
Chronic 0.1 (0.05–0.15) Hollingsworth et al. (2008)
Treatment eligiblea (no ART) 0.43 (0.27–0.62) Hollingsworth et al. (2008)
Treatment eligiblea (ART) 0.003 Del Romero et al. (2010), Wilson et al. (2008) and
Donnell et al. (2010)
Acquisition if negative 0.075 (0.03–0.1) Brown et al. (2011) and Hollingsworth et al. (2008)
Costs (in 2010 US$)b
Personnel
Provider hourly wage $2 ($1.40–$2)
Provider time (additional counselling
for index patients) (min)
5 (3–10)
Provider time (tracing) (min) 35 (25–90)
Provider time (testing notified partners) (min) 30 (20–45)
Driver hourly wage $1.40 ($1–$2.40)
Driver time (tracing) (min) 35 (25–90)
Supervisor costc $532 ($304–$760)
Tracing and transportation
Tracing distance (km) 15 (5–25)
Fuel costs per km (car) $0.24 ($0.19–$0.29)
Fuel costs per km (motorbike) $0.09 ($0.07–$0.10)
Yearly cost of vehicle (car)c $3750 ($3000–$4500)
Yearly cost of vehicle (motorbike)c $400 ($320–$480)
(continued)
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risk of transmission for persons on ART was accounted for
and adjusted based on the likelihood of loss to follow-up across
1 year (Wilson et al. 2008; Del Romero et al. 2010; Donnell et al.
2010). This retention in care and associated transmission
probabilities were also applied to index patients who could
then transmit to HIV-negative partners in the model. All
HIV-infected patients are eligible to transmit to HIV-uninfected
persons for the full year. Given the heterogeneity of treatment
efficacy, comorbidities and acquired or developed resistance to
therapy, differential 1-year ART survival projections are beyond
the scope of this study.
We estimated rates of infection among partners who declined
testing or did not return. Given the high risk of HIV infection
among sexual partners of HIV-infected persons, the Malawian
adult HIV prevalence was an inadequate estimate (WHO 2008;
UNAIDS 2009). Therefore, we assumed the prevalence of
partners who did not test was the same as the prevalence of
those who did according to the empirical results of the trial
(WHO 2008; UNAIDS 2009; Brown et al. 2011). Uncertainty in
this estimate is reflected in the wide range used in sensitivity
analyses to explore this parameter’s potentially substantial role
in cost-effectiveness estimates.
Among partners agreeing to HIV testing there are three
possible outcomes: (1) the partner is identified as HIV negative,
(2) the partner is diagnosed as HIV positive for the first time or
(3) the partner is diagnosed as HIV positive and was already
aware of this serostatus. HIV-negative partners who do not
dissolve the partnership with the index case are now in a
serodiscordant partnership. The probability of reduced risk
behaviours among HIV-serodiscordant couples is substantial
(Allen et al. 1992, 2003; Voluntary HIV-1 Counseling and
Testing Efficacy Study Group 2000; Denison et al. 2008; Celum
et al. 2010; Kennedy et al. 2010; Cohen et al. 2011; Baeten et al.
2012; Hughes et al. 2012; Rosenberg et al. 2012). In this model,
we assumed that 35% of partners who test HIV negative change
behaviour, reducing the risk of HIV acquisition from the
HIV-infected index partner. To account for uncertainty in this
assumption, we varied this base-case value (20–50%). We
assumed that persons who change behaviour modify risky
activities such that they are fully protected from acquisition or
transmission (i.e. 100% condom use, abstinence, etc.) (Crepaz
et al. 2006; Metsch et al. 2008; Kennedy et al. 2010). No
behaviour change is assumed for partners who test HIV
positive. This represents a conservative approach. In addition,
no behaviour change is assumed for partners who are neither
notified nor tested (Weinhardt et al. 1999; Denison et al. 2008).
We conducted one-way and probabilistic sensitivity analyses to
assess the impact of these assumptions on estimated ICERs.
The likelihood of HIV acquisition for partners assumes a
stable partnership between the index and the tested partner;
most partners who are locatable and who agree to testing are
main or steady partners (Kissinger et al. 2003; Brown et al.
2011). Based on observed distribution of CD4 counts among
index partners in the primary study, 37% of index cases were
identified as being treatment eligible and were placed on
therapy. Using the same estimated retention in ART care as
applied to partners in the model (70%), transmission probabil-
ity to an HIV-negative partner from the index partner was
constructed as a weighted average, between index cases
retained on ART and the remaining being in the chronic
stage of infection and not on ART (Brown et al. 2011).
Cost inputs
The incremental costs associated with partner notification were
derived from resources required to trace, test and counsel, and
potentially treat partners of newly diagnosed HIV-positive
indexes (Table 1). The incremental cost of integrating partner
notification into an existing STI clinic is expressed in 2010 US
dollars (US$). Many cost parameters were provided in Kwacha
(Malawian currency) directly from a district hospital in
Lilongwe.1 We use a nominal exchange rate of 150 Kwacha/
2010 US$ (Financial Management Service).
The costs of adverse events that may result from partner
notification, including partner violence or partnership dissol-
ution (Rothenberg et al. 1995; Maher et al. 2000; Maman et al.
2001), were excluded from this analysis. Adverse events were
extremely rare in the Malawi-based trial (Brown et al. 2011). In
Table 1 Continued
Parameter Base case (range) References
Cost of insurance (car)c $2667 ($2400–$2933)
Cost of insurance (motorbike)c $267 ($240–$293)
Testing and treatment
Cost of condoms (10 per person tested) $0.30 ($0.10–$0.50)
Rapid antibody HIV test kits $2 ($1–$3)
Consumables $1 ($0.80–$1.20)
Cost of care (non-ART) $100 ($80–$120) Malawi Ministry of Health (Kamoto and Schouten 2007),
CHAI 2012 ART Pricing List
Cost of care (ART) $285 ($228–$342) Malawi Ministry of Health (Kamoto and Schouten 2007),
CHAI 2012 ART Pricing List
Trainingc $152 ($122–$183)
CN, contract notification; PN, provider notification; PR, passive referral.
aTreatment eligible are those persons testing with a CD4 250 cells/mm3.
bAll costs from personal communication with administrators at UNC Project in Lilongwe unless otherwise indicated.
cFixed year-one costs, not dependent on partner return or testing rate.
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addition, among women visiting an antenatal clinic in a similar
setting, adverse events were not increased among women who
disclosed their HIV status to their partners (Semrau et al. 2005).
Personnel costs were captured as a proportion of full-time
work dedicated to notification services. Salaries were trans-
formed into hourly wages based on the assumption of full-time
employment equivalent to 2000 h/year. We assumed that
partners of indexes would not otherwise seek HIV testing
during the 12-month period, and thus include the time for pre-
and post-test counselling (Zanera and Miteka 2004).
Transportation costs (fuel, insurance and driver time) were
calculated using the average distance travelled to notify
partners in the Lilongwe catchment area, a base case of
15 km and a range of 5–25 km. Providers attempted to locate all
partners in the provider notification arm. Tracing costs are
lower in the contract notification arm, as a proportion of
partners are expected to return within the predefined 1-week
period after notification by the index. No tracing costs are
associated with the passive referral arm.
The costs associated with care and treatment for HIV-positive
persons are fully subsidized by the government in Malawian
public clinics and were included as a cost for all who tested
positive in this model. Costs in the model did not account for
the expense of HIV-related hospitalizations. We assumed a 50%
loss to follow-up from care among persons who test positive
but are not eligible for ART, and conducted one-way sensitivity
varying this from 30 to 70% (Zachariah et al. 2010; Rosen and
Fox 2011). Persons not retained in care do not accumulate costs
of pre-ART care, such as drugs for HIV-related opportunistic
infections, broad-spectrum antibiotics for prophylaxis against
opportunistic infections and other staff and laboratory support
costs. ART expenses account for most treatment costs [inflated
from 2007 US$ using Malawi gross domestic product (GDP)
implicit price deflator] (Kamoto and Schouten 2007; Malawi
Country Report). Prices were also estimated using Clinton
Health Access Initiative (CHAI) price lists for ART in Malawi
from May 2012. We assumed 70% of all eligible persons, as
assessed by CD4 count at diagnosis, begin and adhere to ART.
Sensitivity analyses
Deterministic (one-way univariate) and probabilistic (multi-
variate) sensitivity analyses were performed to assess the
robustness of the assumptions in the decision model (Briggs
2000). One-way sensitivity analyses were conducted for par-
ameters identified as major drivers of the ICER for either
provider or contract notification. Probabilistic sensitivity ana-
lyses using Monte Carlo simulations (5000 trials) were executed
with Crystal Ball version 11.1.2 (Oracle, Redwood Shores, CA,
USA). To assess variation in input parameters and assumptions,
probabilities assumed beta distributions and all costs assumed
gamma distributions. Distribution of probabilities was based
on observed ranges reported in primary literature (Table 1).
Where data were lacking or unavailable, assumption ranges
were generally set to 0.25.
An alternative scenario assessed the use of a motorbike for
tracing in the provider and contract notification arms, instead
of the base-case assumption of a car and driver. Cost savings in
the motorbike scenario include reduced vehicle and driver costs,
improved gas efficiency, faster travel time and lower insurance
premiums. An additional scenario considered the possibility
of patients who test negative being in the acute phase of HIV
infection.
Results
In our model of 5000 locatable partners of HIV-positive indexes,
we estimated that 2436 and 2537 would receive HIV testing
services in the provider and contract notification arms, respect-
ively, compared with 1207 returning for testing with passive
referral. Provider notification identified 1267 new HIV cases
and contract notification identified 1320 new cases compared
with 627 in the passive referral arm.
We conducted sequential comparisons rank ordered by total
cost (Gold et al. 1996; Muennig 2008). Passive referral was the
least expensive, followed by contract notification. Provider
notification was the most costly. The effectiveness of each
alternative strategy was evaluated as transmissions averted,
compared with the next most expensive strategy. We estimated
that compared with passive referral, contract notification would
avert 27.5 transmissions over 1 year. Our base-case analysis
comparing contract notification with passive referral resulted in
an ICER of $3560 per transmission averted (Table 2). Although
more expensive than contract notification, provider notification
averts an additional 0.4 transmissions over 1 year, correspond-
ing to an ICER of $51 421 per transmission averted.
In some settings, provider notification may be a more viable
or operationally preferable option compared with contract
notification based on site-specific factors such as staffing
constraints, clinic catchment areas and testing volumes. In
light of this, we compared provider notification with passive







Passive referral $77 411 233.9 – – –
Contract notification $175 468 206.4 $98 058 27.5 $3560
Provider notification $191 798 206.0 $16 330 0.4 $51 421
Provider notification vs passive referral scenario
Passive referral $77 411 234.0 – – –
Provider notification $191 798 206.0 $114 387 28.0 $4106
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referral. The associated ICER is $4106 per transmission averted
(Table 2—‘provider notification vs passive referral scenario’).
Excluding the cost of treatment for persons identified as
positive, the cost per new case identified was $36, $18 and $8
for provider notification, contract notification and passive
referral, respectively. New identified cases are patients who
are traced or voluntarily return to the clinic and subsequently
receive an HIV-positive test result, excluding the proportion of
persons who test positive and were already aware of their HIV
status. The cost per partner contacted and tested, again
excluding costs associated with treatment for positive partners,
was $19, $9 and $4 for provider notification, contract notifica-
tion and passive referral, respectively. We used costs obtained
directly from the site at which all trial activities were
conducted. We excluded costs that would not be incurred
outside of the trial setting.
Sensitivity analyses
In one-way sensitivity analyses, we estimated the potential
range of ICERs for the strategies, evaluating contract notifica-
tion compared with passive referral, provider notification
compared with contract notification and provider notification
compared with passive referral across the probable range of
input parameters. The results from the most influential input
parameters are presented in Table 3. ICERs were most sensitive
to the probability of persons who did not return being HIV
positive. The wide confidence interval reflects uncertainty of
this estimate (0.34–0.94). The transmission probability for
persons eligible for ART but not on therapy also had a
substantial influence on ICERs, as did the probability that
the index partner was the only partner, with greater partner-
ship dissolutions resulting in more favourable ICERs. At certain
extremes, provider notification was dominated by contract
notification, demonstrating a scenario in which the provider
notification strategy was less effective and more expensive.
Probabilistic sensitivity analysis demonstrates an overall
robust model, where each input parameter is simultaneously
varied across a given range of values from the parameter’s
defined distribution. With each ‘draw’, a new incremental cost
and incremental effectiveness is calculated, as compared with
the referent passive referral. The resulting point estimates are
presented in Figure 2 (ICER planes), representing the ICERs of
the 5000 draws executed through Monte Carlo simulation. The
contract notification strategy is dominated (i.e. the strategy is
both less effective and more costly compared with passive
referral) 7.2% of the time. The provider notification strategy is
dominated 22.9% of the time when compared with contract




Assuming the same number of cases identified when providers
use a motorbike, and excluding the cost of treatment, the
motorbike scenario resulted in an ICER of $3248 per transmis-
sion averted for contract notification, compared with passive
referral. Comparing motorbike tracing to our base case (car and
driver), this ICER corresponds to a cost savings of $312 per case
Table 3 One-way sensitivity analyses comparing partner notification strategiesa









Low High Low High Low High Low High
Probability positive PR (no return) 0.34 0.94 $2843 $4760 $51 421 $51 421 $3287 $5459
Probability of transmission if treatment eligible (no ART) 0.27 0.62 $4707 $2769 $19 532 Dominated $5284 $3254
Probability IP only sexual partner 0.5 0.82 $2683 $4525 Dominated $13 771 $3167 $5008
Probability acquire infection if negative (no behaviour change) 0.03 0.1 $4462 $3200 Dominated $18 429 $5378 $3628
Probability positive (PN) 0.51 0.77 $3560 $3560 $8956 $21 664 $3252 $4855
Probability retained in care among ART-eligible patients 0.5 0.9 $4440 $2960 $22 807 Dominated $5010 $3468
Probability positive (CN) 0.51 0.77 $2705 $4263 $15 628 $6095 $4106 $4106
Probability positive PN (no return) 0.34 0.94 $3560 $3560 Dominated $3406 $4891 $3537
Probability return PN 0.4 0.73 $3560 $3560 $1570 $3625 $4900 $3590
Probability positive CN (no return) 0.34 0.94 $4251 $3062 $3406 Dominated $4106 $4106
Probability behaviour change if negative 0.2 0.5 $4161 $3111 $24 350 Dominated $4730 $3627
Probability test after notification (PN) 0.8 1 $3560 $3560 $20 187 $43 715 $3305 $4363
Probability return PR 0.14 0.34 $3434 $3840 $51 421 $51 421 $3832 $4707
Average tracing distance (km) 5 25 $3482 $3639 $20 629 $82 213 $3678 $4534
Probability lost to follow-up among non-ART-eligible patients 0.3 0.7 $4006 $3114 $54 360 $48 482 $4513 $3698
Probability positive (PR) 0.51 0.77 $3912 $3174 $51 421 $51 421 $4430 $3750
Cost of ARTþ care $228 $342 $3207 $3918 $53 761 $49 081 $3783 $4433
CN, contract notification; IP, index partners; PN, provider notification; PR, passive referral.
aOnly parameters with a CN or PN ICER difference >$650 listed.
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Figure 2 ICER planes. (a) Contract notification vs passive referral. (b) Provider notification vs contract notification. (c) Provider notification vs
passive referral. The probabilistic sensitivity analysis simultaneously varies the input parameters across a given range of values from the parameter’s
distribution. With each draw, a new incremental cost and incremental effectiveness is calculated, as compared with the next least expensive arm.
The resulting point estimates represent the ICERs of the 5000 draws executed with probabilistic sensitivity analyses. In (a) contract notification is
compared with passive referral. In (b) the next most expensive option (provider notification) is compared with contract notification. Finally, in (c)
we compare provider notification with passive referral.
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averted. As with the base-case scenario, provider notification is
slightly more effective but considerably more expensive than
contract notification. Using a motorbike, the cost per new case
identified was $19, $11 and $8 for provider, contract and
passive referral, respectively.
Acute infection
A small percentage of persons who test negative with trad-
itional antibody tests will actually be in the highly infectious
stage of acute HIV infection (AHI) (Pilcher et al. 2004; Powers
et al. 2007; Brown et al. 2011; Pilcher et al. 2007). AHI testing is
not routinely available in STI clinics and these patients will be
misclassified as HIV negative. In this scenario, 3% of patients
who tested negative were assigned transmission probabilities
consistent with AHI (0.178, range 0.09–0.25) (Hollingsworth
et al. 2008; Brown et al. 2011). Including AHI as an infection
state among partners who tested antibody negative did not
qualitatively alter our results.
Discussion
To combat the HIV epidemic in sub-Saharan Africa,
cost-effective, acceptable and feasible interventions to reduce
HIV transmission are necessary. Currently, substantial efforts
are being directed towards prevention strategies that require
significant logistical effort and expense, such as pre-exposure
prophylaxis and provision of ART for prevention. But active
partner notification, a simple, effective and easily implemen-
table strategy, has been largely neglected, relying solely on
passive referral and HIV status disclosure.
We have demonstrated that provider and contract notification
for HIV compare favourably to existing interventions in terms
of cost per HIV case averted, and may be cost-effective
strategies for identifying new cases and averting subsequent
infections in Malawi (Sweat et al. 2004; Menzies et al. 2009). In
our model, provider and contract notification cost only $28 and
$10 more than passive referral, per new case identified. Using a
motorbike for transportation reduces these costs further to only
an additional $11 (provider) and $3 (contract) per new case
identified, compared with passive referral. Contract and pro-
vider notification were more effective than passive referral in
identifying cases and averting secondary transmissions over a
wide range of probability estimates. This work builds upon our
previous trial which demonstrated a high yield of provider-
based notification strategies with minimal adverse conse-
quences (Brown et al. 2011).
Our outcomes, in terms of cost per partner tested and cost per
new HIV case identified, compare favourably to other HTC
strategies. In Uganda, comparing stand-alone, hospital-based,
household-member and door-to-door HTC, cost per HTC client
ranged from $8.29 (door-to-door) to $19.26 (stand-alone) (2007
US$) (Menzies et al. 2009), comparable to the costs of provider
or contract referral in 2010 US$. However, the cost per HIV
infection identified observed in Uganda was much higher than
the cost per HIV infection identified estimated in the model,
ranging from $43 for hospital-based HTC to $232 for
household-member HTC. We observed a cost per new HIV
positive diagnosis of $36 (provider) and $18 (contract),
demonstrating the efficiency of identifying new positives in
the high-risk population of partners of HIV-positive indexes.
These findings likely generalize to other urban STI clinics in
sub-Saharan Africa. Key parameters in our study, including
partner return rates and prevalence of infection, are consistent
with results of partner notification in Cameroon, where more
than 56% of partners were tested through provider notification
and 51% of partners tested were HIV positive, comparable to
the 64% who tested positive in the Malawi trial (Muffih et al.
2009; Brown et al. 2011). Our parameter estimates and model
results may be less applicable to rural settings given potentially
different HIV prevalence, partnership patterns and tracing
distances and associated costs.
Despite the compelling outcomes of the cost per new case
identified, the cost-effectiveness of these provider-initiated
partner notification strategies compared with passive referral
is less certain as no accepted cost-effectiveness threshold exists
for cost per infection averted. The commonly accepted World
Health Organization (WHO) standards of <3 times GDP per
capita as cost effective and <1 times GDP per capita as highly
cost-effective relate to dollar per quality-adjusted life year
outcomes. Importantly, evaluating cost-effectiveness based on
country-specific ability to pay may not apply to the poorest
countries, especially when most resources for HIV prevention
and treatment are provided by external donors (Haacker 2008).
Cost-effectiveness of provider-initiated partner notification
strategies is better assessed through comparison with similar
prevention strategies which evaluate averted infections, such as
the use of nevirapine for prevention of mother-to-child trans-
mission (PMTCT). This strategy is a widely adopted policy
across sub-Saharan Africa and its cost per infection averted
compares favourably with those ICERs observed in this
analysis: a 2004 study found that the cost per infant case
averted ranged from $1808 (Botswana) to $9258 (Côte d’Ivoire)
(2000 US$) (Sweat et al. 2004). Further contextualizing the
outcomes from this study to the Malawian setting, an evalu-
ation of PMTCT from two Malawi health centres identified an
ICER of $998 per infant case averted (2007 US$) (Orlando et al.
2010). Another Malawi-based cost-effectiveness analysis eval-
uated the opportunity to avert HIV infections through expanded
treatment for STI among high-risk males, estimating an ICER
of $15.42 per HIV case averted (2000 US$) (Price et al. 2006).
Importantly, policy makers must consider the cost-effectiveness
of alternative HIV-prevention strategies and the potential
ethical obligations to inform persons who have been exposed
to an HIV-infected partner.
Our findings are likely a conservative estimate of the
cost-effectiveness associated with provider-assisted notification
strategies. The model permits only a single transmission for
each HIV-positive person in serodiscordant partnerships. This
restriction underestimates the total number of transmissions
that may be attributed to an individual, as persons may have
multiple partners. We selected conservative estimates for
behaviour change within serodiscordant couples based on
observed rates of protective behaviour (Kennedy et al. 2010),
and did not include any behaviour change for partners who test
positive. The model also addresses only the first year after
diagnosis, which will underestimate future transmission events
if behaviour change is sustained. In addition, we did not
explicitly model additional expenses, such as hospitalizations
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and lost productivity. Incorporation of these expenses would
improve the cost-effectiveness of strategies that linked persons
into care earlier. Although the cost per new case identified was
higher with the provider-based notification strategies, earlier
entrance into care may be associated with considerable future
savings. Costs due to hospitalization and outpatient visits are
reduced when ART is initiated prior to an AIDS-defining illness
(Harling and Wood 2007). Other costs associated with delayed
linkage into care, such as lost productivity, are difficult to
capture, but their omission from this evaluation likely leads to a
conservative assessment of cost-effectiveness.
As a policy model intended to inform policy makers regard-
ing the potential consequences of incorporating different
notification strategies into existing voluntary HIV counselling
and testing programmes, all costs are limited to a 1-year time
frame—appropriate for budget planning, but limited in that we
are not able to account for costs or transmissions that occur
outside of this time frame. The appropriate strategy and feasible
scalability of a provider-initiated partner notification pro-
gramme will vary by setting, and staffing constraints are not
considered in this model. However, clinic catchment area and
associated tracing distances, which may vary clinic-to-clinic,
had only a minor effect on estimated ICERs. The acceptability
of provider-based partner notification in the urban STI clinic
setting was encouraging, with only 11% refusal in the initial
trial (Brown et al. 2011). However, if index cases were
unwilling to provide partner names or locator information,
the estimated cost-effectiveness of provider-initiated partner
notification programmes would be less favourable. Importantly,
among patients who refused trial participation, 20% refused for
reasons related to fear or unwillingness to notify partners,
which translates to approximately 2% of all potential
participants.
Despite robust, trial-based data, our model assumptions intro-
duce uncertainty into cost-effectiveness estimates. We modelled
HIV protective behaviour as an all-or-nothing change for 35% of
the HIV-negative partners. We would see a similar result if a
higher percentage of persons ‘reduced’ their risky behaviour after
testing, as suggested by recent meta-analysis focused on HIV
behaviour change in low- and middle-income countries
(Kennedy et al. 2010). Lower rates of behaviour change would
reduce the benefits of provider and contract notification relative
to passive referral; higher rates would increase the benefit. We
evaluated the impact of behaviour change in sensitivity ana-
lyses—behaviour change among partners testing HIV negative
had a meaningful impact on estimated cost-effectiveness: varying
the probability of behaviour change from 20 to 50% changes the
estimated ICER to $1050 for contract notification compared with
passive referral. Importantly, in the partner notification setting,
partners who test negative are now likely aware of their being in a
serodiscordant couple, which is associated with high rates of
protective behaviour change (Allen et al. 1992, 2003; Denison et al.
2008; Celum et al. 2010; Cohen et al. 2011; Hughes et al. 2012;
Rosenberg et al. 2012). Even if the partnership has dissolved, this
testing scenario may have a more substantial impact on reducing
risk behaviours as the individual has been directly informed of
HIV exposure. Not shown are scenario analyses in which partners
who test HIV positive are also given a 35% probability of
protective behaviour change, thereby reducing their likelihood of
transmitting to any HIV-negative partners. Behaviour change
among this group decreased the ICER comparing contract
notification to passive referral by $700.
Our primary effectiveness outcome depends on the reliability
of partner return rates and the HIV prevalence among returning
and non-returning partners. The former was empirically
measured by the trial, whereas the latter relied on our
modelling an assumed rate of infection. Data to support
higher or lower rates of infection among partners who did
not return are not available, and compelling arguments can be
made for both scenarios. We accounted for this uncertainty by
incorporating a wide probability distribution. Some notified
partners may have sought alternative testing locations, but the
likelihood of partners seeking testing outside of the
trial-designated clinic was minimized by co-ordinating with
area STI clinics and using study-specific referral cards (Brown
et al. 2011). According to the most recent available data, annual
testing rates for the general population in Lilongwe are 14%
(MOH 2007). We assessed the influence of the underlying
natural testing rate on the model in sensitivity analyses (not
shown). There was no meaningful change in estimated ICERs
when this testing rate was incorporated into the model for
persons who were not notified and, therefore, not tested
through one of the three partner notification strategies. As
such, all testing costs are included in this model as they are
considered incremental expenses that would not otherwise be
incurred. Scenario analyses in which these costs were excluded
had only a minor effect on ICERs. Accurately estimating
transmission rates relies on properly describing infectiousness
of HIV-positive partners. HIV transmission is dynamic, varying
by gender, partner susceptibility, stage of infection, viral
characteristics and treatment. We modelled transmission vari-
ability as amplified by stage of infection, but did not account
for other biological co-factors that contribute to transmission
probability differences, such as STIs. We accounted for the
reduced infectiousness for persons on ART, assuming all eligible
persons immediately began therapy, as occurred in our trial,
estimating retention in care which is relevant for transmission
probabilities and ART-associated costs (Wilson et al. 2008; Del
Romero et al. 2010; Donnell et al. 2010; Brown et al. 2011; Rosen
and Fox 2011). Accounting for the heterogeneity of ART
efficacy across individuals was beyond the scope of this study
and differential survival projections are not included in this
model. The effect that delayed ART initiation and differential
survival would have on model estimates is unknown as it
would reduce costs in all arms, but would also affect expected
transmissions.
Partner notification is a logistically feasible HIV prevention
intervention that has been underutilized in sub-Saharan Africa,
and may be a cost-effective addition to existing testing and
prevention strategies. Alternative solutions that identify persons
earlier in the course of infection may include community- or
home-based testing, and these approaches should be considered
in future cost-effectiveness analyses. Many of the most
promising prevention interventions require reaching large seg-
ments of the population for HIV testing. Active partner
notification, either contract or provider-based, provides an
effective, efficient and likely cost-effective strategy in a
resource-limited setting. Increasing efforts to reach partners of
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known HIV-infected persons is a reasonable and appropriate
adjunct to any HIV prevention programme.
Acknowledgements
S.E.R., L.B.B., A.K.B., N.E.R. and W.C.M. conceptualized the
study. The partner notification trial, from which numerous
parameters were drawn, was conducted by L.B.B., G.K., P.M.,
N.N., I.M., I.F.H. and W.C.M. S.E.R., A.K.B., S.B.W. and
N.E.R. contributed to the initial design and subsequent modi-
fications to the cost-effectiveness model. The manuscript
was drafted by S.E.R. Manuscript revisions were made by
L.B.B., A.K.B., S.B.W., G.K., N.E.R., I.F.H. and W.C.M.
Funding
This work was supported by the University of North Carolina at
Chapel Hill Center for AIDS Research (CFAR), a National
Institutes of Health (NIH)-funded program (#P30 AI50410)
and other NIH grants (1F30MH085431, R01 AI83059,
F30MH098731-01, and T32 GM008719).
Endnote
1 Data obtained from UNC Project administrators, Lilongwe, Malawi.
References
Allen S, Meinzen-Derr J, Kautzman M et al. 2003. Sexual behavior of
HIV discordant couples after HIV counseling and testing. AIDS 17:
733–40.
Allen S, Tice J, Van de Perre P et al. 1992. Effect of serotesting with
counselling on condom use and seroconversion among HIV
discordant couples in Africa. BMJ 304: 1605–9.
Antelman G, Daaya S, Mbwambo J, Fawzi W, Msamanga GI, Hunter D,
Smith Fawzi MC. Year. Factors related to disclosure of an HIV-
positive test result to a sexual partner or any other confidant in
Dar es Salaam, Tanzania. In: Conference on Global Strategies for
Prevention of HIV Transmission for Mothers to Infants. Canada: 1999
Montreal.
Baeten JM, Donnell D, Ndase P et al. 2012. Antiretroviral prophylaxis for
HIV prevention in heterosexual men and women. New England
Journal of Medicine 367: 399–410.
Brewer DD. 2005. Case-finding effectiveness of partner notification and
cluster investigation for sexually transmitted diseases/HIV. Sexually
Transmitted Diseases 32: 78.
Briggs AH. 2000. Handling uncertainty in cost-effectiveness models.
Pharmacoeconomics 17: 479–500.
Brown L, Miller WC, Kamanga G et al. 2011. HIV partner notification is
effective and feasible in sub-Saharan Africa: opportunities for HIV
treatment and prevention. Journal of Acquired Immune Deficiency
Syndrome 56: 437–42.
CDC. 2003. HIV Partner Counseling and Referral Services. Atlanta: CDC.
http://www.cdc.gov/hiv/topics/prev_prog/ahp/resources/guidelines/
Interim_partnercounsel.htm, accessed 10 December 2010.
CDC. 2008. Sexually Transmitted Diseases Surveillance. CDC. http://www.cdc
.gov/std/stats08/tables.htm, accessed 20 November 2009.
Celum C, Wald A, Lingappa JR et al. 2010. Acyclovir and transmission of
HIV-1 from persons infected with HIV-1 and HSV-2. New England
Journal of Medicine 362: 427–39.
Cohen MS, Chen YQ, McCauley M et al. 2011. Prevention of HIV-1
infection with early antiretroviral therapy. New England Journal of
Medicine 365: 493–505.
Crepaz N, Lyles CM, Wolitski RJ et al. 2006. Do prevention inter-
ventions reduce HIV risk behaviours among people living
with HIV? A meta-analytic review of controlled trials. AIDS 20:
143–57.
Del Romero J, Castilla J, Hernando V, Rodriguez C, Garcia S. 2010.
Combined antiretroviral treatment and heterosexual transmission
of HIV-1: cross sectional and prospective cohort study. BMJ 340:
c2205.
Denison JA, O’Reilly KR, Schmid GP, Kennedy CE, Sweat MD. 2008.
HIV voluntary counseling and testing and behavioral risk reduction
in developing countries: a meta-analysis, 1990–2005. AIDS and
Behavior 12: 363–73.
Donnell D, Baeten JM, Kiarie J et al. 2010. Heterosexual HIV-1
transmission after initiation of antiretroviral therapy: a prospective
cohort analysis. Lancet 375: 2092–8.
Efficacy of voluntary HIV-1 counselling and testing in individuals
and couples in Kenya, Tanzania, and Trinidad: a randomised trial.
The Voluntary HIV-1 Counseling and Testing Efficacy Study Group.
Lancet 356: 103–12.
European Partner Notification Study G. 2001. Recently diagnosed
sexually HIV-infected patients: seroconversion interval, partner
notification period and a high yield of HIV diagnoses among
partners. Quarterly Journal of Mathematics 94: 379.
Financial Management Service, Bureau of the US Department of the Treasurey.
Washington DC. http://www.fms.treas.gov/intn.html, accessed 30
December 2010.
Girardi E, Sabin CA, Monforte AD. 2007. Late diagnosis of HIV
infection: epidemiological features, consequences and strategies
to encourage earlier testing. Journal of Acquired Immune Deficiency
Syndrome 46(Suppl 1):S3–8.
Gold MR, Siegel JE, Russell LB, Weinstein MC (eds). 1996. Cost-
Effectiveness in Health and Medicine. New York: Oxford University
Press.
Golden MR, Dombrowski JC, Wood RW, Fleming M, Harrington RD.
2009. A controlled study of the effectiveness of public health HIV
partner notification services. AIDS 23: 133–5.
Haacker M. 2008. Financing the response to AIDS: some fiscal and
macroeconomic considerations. AIDS 22(Suppl 1): S17–22.
Harling G, Wood R. 2007. The evolving cost of HIV in South Africa:
changes in health care cost with duration on antiretroviral therapy
for public sector patients. Journal of Acquired Immune Deficiency
Syndrome 45: 348–54.
Hogben M, McNally T, McPheeters M, Hutchinson AB. 2007.
The effectiveness of HIV partner counseling and referral services in
increasing identification of HIV-positive individuals a: systematic
review. American Journal of Preventive Medicine 33: S89–100.
Hollingsworth TD, Anderson RM, Fraser C. 2008. HIV-1 transmission, by
stage of infection. Journal of Infectious Diseases 198: 687–93.
Hughes JP, Baeten JM, Lingappa JR et al. 2012. Determinants
of per-coital-act HIV-1 infectivity among African HIV-1-
serodiscordant couples. Journal of Infectious Diseases 205: 358–65.
Kamoto K, Schouten E. 2007. 100,000 People Started on ART with Very
Limited Human Resources: Experiences from Malawi. Lilongwe, Malawi:
HIV/AIDS Unit, Ministry of Health.
Kennedy CE, Medley AM, Sweat MD, O’Reilly KR. 2010. Behavioural
interventions for HIV positive prevention in developing countries: a
HIV PARTNER NOTIFICATION COST-EFFECTIVENESS 125
systematic review and meta-analysis. Bulletin of the World Health
Organization 88: 615–23.
Kilewo C, Massawe A, Lyamuya E, Kalokola V, Semali I, Karisson K,
Mhalu F, Biberfield G. Year. HIV testing of pregnant women in
sub-Saharan Afirca: the PETRA experience in Dar es Salaam,
Tanzania. In: XIth International Conference on AIDS and STDs in Africa.
Zambia: 1999 Lusaka.
Kissinger PJ, Niccolai LM, Magnus M et al. 2003. Partner notification for
HIV and syphilis: effects on sexual behaviors and relationship
stability. Sexually Transmitted Diseases 30: 75–82.
Landis SE, Schoenbach VJ, Weber DJ et al. 1992. Results of a
randomized trial of partner notification in cases of HIV infection
in North Carolina. New England Journal of Medicine 326: 101–6.
Leynaert B, Downs AM, de Vincenzi I. 1998. Heterosexual transmission
of human immunodeficiency virus: variability of infectivity
throughout the course of infection. European Study Group on
Heterosexual Transmission of HIV. American Journal of Epidemiology
148: 88–96.
Maher JE, Peterson J, Hastings K et al. 2000. Partner violence, partner
notification, and women’s decisions to have an HIV test. Journal of
Acquired Immune Deficiency Syndrome 25: 276–82.
Malawi Country Report. Global Finance. http://www.gfmag.com/gdp-data-
country-reports/227-malawi-gdp-country-report.html, accessed 27
October 2010.
Maman S, Mbwambo J, Hogan NM, Kilonzo GP, Sweat M. 2001.
Women’s barriers to HIV-1 testing and disclosure: challenges for
HIV-1 voluntary counselling and testing. AIDS Care 13: 595–603.
Marcus JL, Bernstein KT, Klausner JD. 2009. Updated outcomes of
partner notification for human immunodeficiency virus, San
Francisco, 2004-2008. AIDS 23: 1024–6.
Marks G, Crepaz N, Janssen RS. 2006. Estimating sexual transmission
of HIV from persons aware and unaware that they are infected
with the virus in the USA. AIDS 20: 1447.
Mathews C, Coetzee N, Zwarenstein M et al. 2002. A systematic review of
strategies for partner notification for sexually transmitted diseases,
including HIV/AIDS. International Journal of STD & AIDS 13: 285–300.
Menzies N, Abang B, Wanyenze R et al. 2009. The costs and
effectiveness of four HIV counseling and testing strategies in
Uganda. AIDS 23: 395–401.
Metsch LR, Pereyra M, Messinger S et al. 2008. HIV transmission risk
behaviors among HIV-infected persons who are successfully linked
to care. Clinical Infectious Diseases 47: 577–84.
MOH. 2007. Report of a Country-wide Survey of HIV/AIDS Services in Malawi
for the Year 2006. Lilongwe: HIV Unit, Department of Clinical
Services, MOH.
Muennig P. 2008. Cost-effectiveness Analysis in Health: A Practical Approach.
San Francisco: John Wiley & Sons.
Muffih PT, Forgwei G, Welty T, Welty S, Harrington C. 2009. Integrated
Contact/Tracing Partner Notification in Cameroon: a feasible HIV
infection risk reduction intervention for resource-poor settings.
International AIDS Society Conference. Cape Town, South Africa.
Orlando S, Marazzi MC, Mancinelli S et al. 2010. Cost-effectiveness
of using HAART in prevention of mother-to-child transmission in
the DREAM-Project Malawi. Journal of Acquired Immune Deficiency
Syndrome 55: 631–4.
Pilcher CD, Joaki G, Hoffman IF, Martinson FE, Mapanje C, Stewart P,
Powers KA, Galvin S, Chilongozi D, Gama S, Price MA, Fiscus SA,
Cohen MS. 2007. Amplified transmission of HIV-1: comparison of
HIV-1 concentrations in semen and blood during acute and chronic
infection. AIDS 21: 1723–30.
Pilcher CD, Price MA, Hoffman IF et al. 2004. Frequent detection of
acute primary HIV infection in men in Malawi. AIDS 18: 517–24.
Powers KA, Miller WC, Pilcher CD et al. 2007. Improved detection of
acute HIV-1 infection in sub-Saharan Africa: development of a risk
score algorithm. AIDS 21: 2237–42.
Price MA, Stewart SR, Miller WC et al. 2006. The cost-effectiveness of
treating male trichomoniasis to avert HIV transmission in men
seeking sexually transmitted disease care in Malawi. Journal of
Acquired Immune Deficiency Syndrome 43: 202–9.
Rahman M, Fukui T, Asai A. 1998. Cost-effectiveness analysis of partner
notification program for human immunodeficiency virus infection
in Japan. Journal of Epidemiology 8: 123–8.
Rosen S, Fox MP. 2011. Retention in HIV care between testing and
treatment in sub-Saharan Africa: a systematic review. PLoS Medicine
8: e1001056.
Rosenberg N, Pettifor A, Delany-Moretlwe S et al. 2012. Couples HIV
testing and counseling leads to immediate and sustained consistent
condom use among South African stable HIV discordant couples.
International AIDS Conference. Washington DC.
Rothenberg KH, Paskey SJ, Reuland MM, Zimmerman SI, North RL.
1995. Domestic violence and partner notification: implications for
treatment and counseling of women with HIV. Journal of American
Medical Women’s Association 50: 87–93.
Semrau K, Kuhn L, Vwalika C et al. 2005. Women in couples antenatal
HIV counseling and testing are not more likely to report adverse
social events. AIDS 19: 603–9.
Shrestha RK, Begley EB, Hutchinson AB et al. 2009. Costs and
effectiveness of partner counseling and referral services with
rapid testing for HIV in Colorado and Louisiana, United States.
Sexually Transmitted Diseases 36: 637–41.
Sweat MD, O’Reilly KR, Schmid GP, Denison J, de Zoysa I. 2004.
Cost-effectiveness of nevirapine to prevent mother-to-child HIV
transmission in eight African countries. AIDS 18: 1661–71.
Temmerman M, Ndinya-Achola J, Ambani J, Piot P. 1995. The right not
to know HIV-test results. Lancet 345: 969–70.
UNAIDS. 2009. AIDS Epidemic Update. Joint United Nations Programme
on HIV/AIDS (UNAIDS) & WHO. Geneva, Switzerland.
Varghese B, Peterman TA, Holtgrave DR. 1999. Cost-effectiveness of
counseling and testing and partner notification: a decision analysis.
AIDS 13: 1745–51.
Wawer MJ, Gray RH, Sewankambo NK et al. 2005. Rates of HIV-1
transmission per coital act, by stage of HIV-1 infection, in Rakai,
Uganda. Journal of Infectious Diseases 191: 1403–9.
Weinhardt LS, Carey MP, Johnson BT, Bickham NL. 1999. Effects
of HIV counseling and testing on sexual risk behavior: a meta-
analytic review of published research, 1985-1997. American Journal
of Public Health 89: 1397–405.
WHO. 2008. Epidemiological Fact Sheet on HIV and AIDS: Core Data on
Epidemiology and Response. Geneva, Switzerland: WHO Press.
Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. 2008. Relation
between HIV viral load and infectiousness: a model-based analysis.
Lancet 372: 314–20.
Zachariah R, Taylor Smith K, Manzi M et al. 2010. High loss to follow up
rate among individuals in urgent need of antiretroviral treatment
in Malawi and Kenya. Cohort reporting that does not include this
group is biased and misleading! Vienna: IAS.
Zanera D, Miteka I. 2005. Chapter 11: HIV/AIDS and Other Sexually
Transmitted Infections. Malawi Demographic and Health Survey. Zomba,
Malawi: National Statistical Office.
126 HEALTH POLICY AND PLANNING
